Combination of 1-blockers and phosphodiesterase type 5 inhibitor in patients with benign prostatic hyperplasia and erectile dysfunction : results of observatory prospective multicenter study
AIM: To evaluate the efficacy and safety of combination therapy with 1-blocker and phosphodiesterase type 5 inhibitor (PDE5) in patients with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED).
MATERIALS AND METHODS: The observational multicenter program involving 18 medical institutions in Moscow included 315 men aged 40-65 years with BPH and ED. The inclusion criteria were a total IPSS score more than 8 points, QoL score of more than 3 points and clinical manifestations of ED ( less or equal 20 points on the IIEF-5 score). All patients received combined pharmacotherapy with Alfuprost MP 10 mg/day and Viatail 50 mg/day (if necessary, the dose was increased to 100 mg/day) for 3 months.
RESULTS: The combination therapy showed a high clinical efficiency and a favorable safety profile. Lower urinary tract symptoms improved by more than 60%, QoL increased by 64% and erectile function improved in more than 80% of patients. At the end of treatment, the average patient satisfaction score on the Likert scale was 4.2 (high and very high satisfaction), while doctors satisfaction with the clinical response of patients to the treatment was 4.35 points, which also corresponds to high and very high efficacy of therapy.
CONCLUSION: Combination of Alfuprost MP 10 mg/day and Viatail 50 mg/day (100 mg, if necessary) can be considered as one of the best options for non-surgical treatment of patients with BPH and ED.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
Urologiia (Moscow, Russia : 1999) - (2020), 3 vom: 26. Juni, Seite 50-55 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Borisov, V V [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 17.09.2020 Date Revised 31.05.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM311756964 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311756964 | ||
| 003 | DE-627 | ||
| 005 | 20231225142935.0 | ||
| 007 | tu | ||
| 008 | 231225s2020 xx ||||| 00| ||rus c | ||
| 028 | 5 | 2 | |a pubmed24n1039.xml |
| 035 | |a (DE-627)NLM311756964 | ||
| 035 | |a (NLM)32597586 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Borisov, V V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combination of 1-blockers and phosphodiesterase type 5 inhibitor in patients with benign prostatic hyperplasia and erectile dysfunction |b results of observatory prospective multicenter study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 17.09.2020 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: To evaluate the efficacy and safety of combination therapy with 1-blocker and phosphodiesterase type 5 inhibitor (PDE5) in patients with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) | ||
| 520 | |a MATERIALS AND METHODS: The observational multicenter program involving 18 medical institutions in Moscow included 315 men aged 40-65 years with BPH and ED. The inclusion criteria were a total IPSS score more than 8 points, QoL score of more than 3 points and clinical manifestations of ED ( less or equal 20 points on the IIEF-5 score). All patients received combined pharmacotherapy with Alfuprost MP 10 mg/day and Viatail 50 mg/day (if necessary, the dose was increased to 100 mg/day) for 3 months | ||
| 520 | |a RESULTS: The combination therapy showed a high clinical efficiency and a favorable safety profile. Lower urinary tract symptoms improved by more than 60%, QoL increased by 64% and erectile function improved in more than 80% of patients. At the end of treatment, the average patient satisfaction score on the Likert scale was 4.2 (high and very high satisfaction), while doctors satisfaction with the clinical response of patients to the treatment was 4.35 points, which also corresponds to high and very high efficacy of therapy | ||
| 520 | |a CONCLUSION: Combination of Alfuprost MP 10 mg/day and Viatail 50 mg/day (100 mg, if necessary) can be considered as one of the best options for non-surgical treatment of patients with BPH and ED | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a 1-blocker | |
| 650 | 4 | |a benign prostatic hyperplasia | |
| 650 | 4 | |a erectile dysfunction | |
| 650 | 4 | |a phosphodiesterase type 5 inhibitors | |
| 650 | 7 | |a Carbolines |2 NLM | |
| 650 | 7 | |a Phosphodiesterase 5 Inhibitors |2 NLM | |
| 650 | 7 | |a Tadalafil |2 NLM | |
| 650 | 7 | |a 742SXX0ICT |2 NLM | |
| 650 | 7 | |a Cyclic Nucleotide Phosphodiesterases, Type 5 |2 NLM | |
| 650 | 7 | |a EC 3.1.4.35 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Urologiia (Moscow, Russia : 1999) |d 1999 |g (2020), 3 vom: 26. Juni, Seite 50-55 |w (DE-627)NLM110630386 |x 1728-2985 |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g number:3 |g day:26 |g month:06 |g pages:50-55 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |e 3 |b 26 |c 06 |h 50-55 | ||